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All patients are entitled to equal access to health care re-
sources. The Department of Pharmacoeconomics at Uni-
versity of Texas MD Anderson Cancer Center (UTM-
DACC) administers a Patient Assistance Program (PAP)
that provides assistance to indigent patients with free
pharmaceuticals for their therapy. Drug cost is recovered
through a drug reimbursement program offered by phar-
maceutical companies. OBJECTIVE: The objective of
this report is to examine trends in drug cost savings to in-
digent patients at UTMDACC using the PAP model.
METHODS: A retrospective study using data from Sep-
tember 1996 to August 2000 was conducted to determine
the value of the program. Patients were enrolled in this
program if they qualified based on the Financial Classifi-
cation Scale. Uninsured patients as well as under-insured
patients were considered in this study. Data was analyzed
to evaluate the trend in cost savings for the three fiscal
years. RESULTS: Over $334 million was spent on drug
cost over the period. There was an average increase of
22% per year in drug cost. The indigent patients ac-
counted for 9% of the total patient population at UTM-
DACC. An estimated $33 million was spent on drugs for
indigent patients during that period. The PAP system re-
covered a total of $16.8 million; $4.1M (1997), $4.3M
(1998), $3.5M (1999), and $4.9M (2000). This accounts
for 51% in drug cost recovery through this program. The
fluctuation in cost saving was attributed to changes in the
number of programs, number of patients enrolled, and
product mix. CONCLUSION: The PAP system has pro-
vided free drugs to patients without financial resources
and reduced the economic burden of this population on
the health care institution. The program has created
goodwill between the pharmaceutical companies, the
health care institution, the patients and the community.
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LESSONS LEARNED FROM DEVELOPING A 
PSYCHOMETRICALLY BASED SEDATION 
QUESTIONNAIRE IN PHARMACOLOGICALLY 
PARALYZED CRITICALLY ILL PATIENTS
Kane SL, Dasta JF, Pathak DS
The Ohio State University, Columbus, OH, USA
OBJECTIVE: To share lessons learned from developing a
reliable and valid questionnaire for adequacy of sedation
in pharmacologically paralyzed critically ill patients.
METHODS: In phase 1, seven experts listed 21 charac-
teristics describing anxiety in pharmacologically para-
lyzed patients. In phase 2, two scenarios were created il-
lustrating the experience of paralysis: one with and one
without receiving a sedative. A convenience sample of 30
people evaluated scenarios to determine the importance
of characteristics obtained from phase 1 using a five-
point scale. Items were reduced to the 10 most important
characteristics (mean 
3). Based on these results, the fi-
nal instrument consisted of 12 questions: 2 categorical
addressing memory of the experience and 10 referred to
characteristics of anxiety. In phase 3, two groups of criti-
cally ill patients were administered the questionnaire: 1)
sedated only and 2) sedated and pharmacologically para-
lyzed. The questionnaire was administered twice for reli-
ability. Questionnaire results were compared to subjec-
tive and objective sedation monitoring tools for validity.
Calculated sample size was 20 for each group. RESULTS:
During six months, 21 patients consented to participate.
Twelve patients died and nine patients (6 sedated, 3 se-
dated/paralyzed) were administered questionnaires. Five
patients (3 sedated, 2 sedated/paralyzed) did not remem-
ber the intensive care unit experience. Two of three pa-
tients in the sedated group who answered the question-
naire found it difficult to remember over time. One
sedated/paralyzed patient who answered the question-
naire received a sedative without amnesic properties and
felt anxious during therapy. The distressful feeling of this
patient was comparable to findings of the objective seda-
tion tool. CONCLUSIONS: Mortality in this critically ill
patient population was high. Due to amnestic properties
of sedatives most patients did not remember the experi-
ence. Of patients who remembered, their memory deteri-
orated over time. Based on lessons learned, it may require
2–3 years to achieve the necessary sample size.
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ROLE OF HEALTH RELATED QUALITY OF LIFE 
OUTCOMES IN THE EUROPEAN DRUG 
REGULATORY PROCESS: A REVIEW OF THE 
EMEA DOCUMENTS
Acquadro C, Staniek V, for the ERIQA Group
Mapi Research Institute, Lyon, France
INTRODUCTION: The ERIQA Group aims to create
guidance for European regulatory authorities on the as-
sessment of the quality of HRQL studies in clinical trials
and to evaluate the validity of HRQL claims. OBJEC-
TIVES: To identify disease or drugs in which a formal
HRQL assessment is recommended. To identify measures
and methods recommended. To evaluate the reliability of
recommendations across documents. METHODS: Infor-
mations were searched on the EMEA website (www.
eudra.org/emea.html). A research was performed with
the two key words: “Quality of life” and “QoL”. All the
documents retrieved were reviewed. RESULTS: 133 doc-
uments were retrieved excluding duplicates (129: Quality
of Life, 25: QoL). 19 documents derived from the Effi-
cacy Working Parties (EWP) including nine notes for
guidance (Weight Control, Cancer, Chronic Peripheral
Arterial Occlusive Disease, Cardiac Failure, Stable An-
gina Pectoris, Antiarrythmics, Parkinson, Alzheimer,
Multiple Sclerosis), concept paper (3), points to consider
(5) and position statements (2). Only one document was
a note for guidance for ICH. 104 European Public As-
sessment Report (EPAR) were retrieved, representing 26
products. Nine miscellaneous documents were found in-
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cluding minute reports, workshop, letters (5), assessment/
opinion (2) from the CPMP and 2 documents were pro-
duced by the CVMP. CONCLUSIONS: The recommen-
dations from the EMEA are vague in most cases, too ge-
neric, inconsistent between each other and reveal in some
cases a lack of knowledge of the field. These recommen-
dations are not up-dated and do not exist in relevant dis-
eases (HIV/AIDS, HBP). Nevertheless, recommendations
do exist showing a real interest in HRQL and recognition
of HRQL as a valuable endpoint (mainly secondary).
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DEFINING CLINICALLY MEANINGFUL CHANGE 
IN HEALTH-RELATED QUALITY OF LIFE
Crosby RD1, Kolotkin RL2, Williams GR3
1Neuropsychiatric Research Institute, Fargo, ND, USA; 2Duke 
Medical Center, Durham, NC, USA; 3Knoll Pharmaceuticals, 
Mount Olive, NJ, USA
OBJECTIVES: This paper reviews current approaches to
defining clinically meaningful change in health-related
quality of life (HRQOL). METHODS: Definitions of
clinically meaningful change are discussed. Psychometric
properties of HRQOL instruments necessary for identify-
ing clinically meaningful change are identified. Two broad
methods for identifying clinically meaningful change are
contrasted: anchor-based methods and distribution-based
methods. Anchor-based methods include forced-choice
paradigms, global change ratings, receiver operating char-
acteristic techniques, goal attainment scaling and exter-
nal event methods. Distribution-based methods include
individual effect size, the Guyatt responsiveness index,
the Jacobson-Traux reliable-change index (and subsequent
variations), standard error of measurement, and hierar-
chical linear modeling. Strategies for validating clinically
meaningful change measures are discussed. RESULTS:
Anchor-based and distribution-based methods have both
advantages and limitations, and neither appears superior
to the other. Anchor-based methods provide a source for
external validation, but are dependent on the specific an-
chors being used. Distribution-based methods provide a
statistical basis for decision-making, but may vary on the
basis of sample characteristics. CONCLUSIONS: The use
of multiple methods to define clinically meaningful change
is strongly recommended. Factors to consider in defining
clinically meaningful change include the severity of the
baseline value, the direction of change, and the impor-
tance of the change to the individual.
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CROSS-CULTURAL VARIATIONS IN SF-12 
SCORES AMONG INDIVIDUALS WITH VARIOUS 
HEALTH CONDITIONS
Bolge SC, Eschmann B, Donohue JA
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To examine the cross-cultural differences
of health-related quality of life among people with vari-
ous health conditions across four countries. METHODS:
Analyses were based on 12-page questionnaires mailed to
adults in 2000. A total of 38,677 responses were received
from France, Germany, Great Britain, and the US Results
were subsequently weighted and projected to the national
populations of these four countries. Weighting was based
on gender, age, and region for the European countries
and gender, age, race, and region for the US Participants
reported whether they were diagnosed with the follow-
ing: arthritis, asthma, depression, diabetes, GERD, high
blood pressure, high cholesterol, migraines, nasal aller-
gies, or osteoporosis. Physical and mental health status
were defined by summary measures of the SF-12 scale.
RESULTS: The French reported lower mental health sta-
tus but better physical health status than people in Ger-
many, Great Britain, and the US, regardless of diagnosed
health conditions. The opposite was found among arthri-
tis, asthma, and GERD sufferers in Germany, who re-
ported the best mental health status but the lowest physi-
cal health. Respondents from Great Britain and the US
generally reported SF-12 scores that fell between those of
France and Germany, with three notable exceptions.
Among people diagnosed with depression, those in the
US reported better mental health status. Among people
diagnosed with high blood pressure or high cholesterol,
those in Great Britain reported the lowest physical health
status. CONCLUSION: Self-reported quality of life var-
ied by country regardless of condition. Researchers
should consider cross-cultural variations in self-reported
quality of life measures when conducting multinational
trials. Collapsing data could obscure effects.
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TRANSLATING SF-36 SCORES INTO 
PREFERENCES: AN EXAMINATION OF THE 
PERFORMANCE OF TWO
PREDICTIVE EQUATIONS
Meletiche DM, Roberts CS, Lofland JH
Thomas Jefferson University, Philadelphia, PA, USA
Despite widespread use of the SF-36, its use in cost-utility
analyses has been precluded by its inability to measure
patient preferences. To overcome this obstacle, various
investigators have derived equations to estimate prefer-
ence scores from the SF-36. OBJECTIVE: To compare
two methods of estimating preference values from SF-36
scores. METHODS: A convenience sample of patients
completed the SF-36 and EuroQol during their initial
visit to a specialty headache center. Preference scores
were estimated from the SF-36 using two equations, one
developed by Fryback and the other by Brazier. The per-
formance of each equation was assessed by calculating
the correlation coefficient between the estimates and ac-
tual preference scores from the EuroQol. Mean prefer-
ence scores from each method were compared using one-
way repeated measures ANOVA. RESULTS: Forty-seven
